Table 3.
Studies investigating the role of FKBP51 in antidepressant response.
| Ref. | FKBP5 Measure | Sample | Finding |
|---|---|---|---|
| [196] | mRNA levels in blood | Patients with MDD (n = 74) and healthy controls (n = 34) | Association between successful antidepressant response and reduction of FKBP5 mRNA levels after 8 weeks of treatment with escitalopram or nortriptyline. |
| [202] | Genotype (rs1360780, rs3800373) | N = 246 geriatric patients with depression | No association between FKBP5 and clinical outcomes after 8 weeks of treatment with paroxetine and mirtazapine. |
| [226] | Genotype (rs1360780) | Depressive outpatients (n = 159) and controls (n = 96) | T allele carriers showed a 2.10 increased risk for non-responding at 4th week to 12-week citalopram treatment (almost significant tendency). |
| [197] | Genoytpe (rs3800373, rs1360780) | N = 304 depressive inpatients with unipolar or bipolar depression | Carriers of the FKBP5 variants had a trend toward a higher chance to response (mainly in those treated with antidepressant drug combinations or with venlafaxine) |
| [203] | Genotype (rs1360780) | N = 125 outpatients with major depression (n = 119) or dysthymic disorders (n = 6) | No association between rs1360780 and short-term antidepressant treatment response (fluoxetine; 20 mg/day) or lifetime depressive episodes. |
| [12] | Genotype (several SNPs) | N = 233 depressed inpatients | Association between three SNPs in FKBP5 (rs1360780, rs1334894 and rs755658) with antidepressant response. In a replication sample, rs1360780 showed a significant association and rs3800373 showed a trend for an association with response to antidepressants. |
| [198] | Genotype (rs1360780) | N = 1953 STAR*D outpatients and N = 275 MARS in patients | Interaction between the TT genotype of FKBP5 rs1360780 and the GG genotype of GRIK4 (rs12800734) in the prediction of antidepressant response. |
| [199] | Genotype (rs1360780) | N = 298 inpatients with MDD | Interaction between FKBP5 genotype at rs1360780 and treatment mode. C-allele carriers had a significantly worse outcome when treated naturalistically. TT-genotype subjects showed a superior treatment response across both SSTR and TAU treatment conditions. |
| [200] | Genotype (several SNPs) | N = 529 MDD patients from the Mayo clinic and n = 96 from the STAR*D study | Association between the SNP rs352428 with 8-week SSRI treatment response in the Mayo study and 6-week treatment response in the STAR*D replication study. |
| [201] | Genotype (rs1360780, rs4713916) | Outpatients with non-psychotic MDD (n = 1809) and controls (n = 729) | rs1360780 was significantly associated with MDD in White non-Hispanics. Significant association between rs4713916 and remission. |
| [204] | Genotype (rs1360780, rs3800373) | Meta-analysis with a total sample of 2,194 subjects for rs1360780 and 2,049 for rs3800373 | rs1360780: In Caucasians T-allele carriers showed a marginal evidence of better response, while in the other/mixed ethnic subgroup a better response was seen in C/C homozygous subjects. rs3800373: In Caucasians C-allele carriers showed a trend of better response. |
MARS = Munich Antidepressant Response Signature; MDD = major depressive disorder; SSTR = structured, stepwise treatment algorithm; STAR*D = Sequenced Treatment Alternatives to Relieve Depression; TAU = treatment as usual.